Masayuki Nigo

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

José M. Munita, Samuel L Aitken, William R. Miller et al. · Clinical Infectious Diseases · 2017 · 134 citations · Full text

Multicenter Evaluation, Antimicrobial Chemotherapy, Drug Resistance +16

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients

Mila B. Ortigoza, Hyunah Yoon, Keith Goldfeld et al. · JAMA Internal Medicine · 2021 · 91 citations · Full text

Recurrent neural network models (CovRNN) for predicting outcomes of patients with COVID-19 on admission to hospital: model development and validation using electronic health record data

Laila Rasmy, Masayuki Nigo, Bijun S. Kannadath et al. · The Lancet Digital Health · 2022 · 82 citations · Full text

What’s New in the Treatment of Enterococcal Endocarditis?

Masayuki Nigo, José M. Munita, César A. Arias et al. · Current Infectious Disease Reports · 2014 · 52 citations · Full text

Antibiotics, Gastroenterology, Sepsis +5

Two Cases of Fatal Hyperammonemia Syndrome due to Mycoplasma hominis and Ureaplasma urealyticum in Immunocompromised Patients Outside Lung Transplant Recipients

Cima Nowbakht, Angelina Edwards, David Rodriguez‐Buritica et al. · Open Forum Infectious Diseases · 2019 · 49 citations · Full text

Urology, Mycoplasma Hominis, Kidney Transplant +5